PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26298772-2	2015	We developed a new CAR directed against the disialoganglioside GD2, a surface molecule expressed in neuroblastoma and in other neuroectoderm-derived neoplasms.	sialogangliosides	44-62	nuclear receptor subfamily 1 group I member 3	Homo sapiens	19-22	
34382720-1	2021	Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma.	sialogangliosides	0-18	nuclear receptor subfamily 1 group I member 3	Homo sapiens	34-59	
34382720-1	2021	Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma.	sialogangliosides	0-18	nuclear receptor subfamily 1 group I member 3	Homo sapiens	61-64	
34382720-1	2021	Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma.	sialogangliosides	0-18	nuclear receptor subfamily 1 group I member 3	Homo sapiens	79-82	
35130560-2	2022	We previously discovered that the disialoganglioside GD2 is highly expressed on H3K27M-mutant glioma cells and demonstrated promising preclinical efficacy of GD2-directed chimeric antigen receptor (CAR) T cells2, providing the rationale for a first-in-human Phase 1 clinical trial (NCT04196413).	sialogangliosides	34-52	nuclear receptor subfamily 1 group I member 3	Homo sapiens	198-201